Glioma Talk
-
Upload
patrick-martineau -
Category
Documents
-
view
231 -
download
3
description
Transcript of Glioma Talk
Tumour Progression or radionecrosis? The role of molecular imaging
Gliomas: The basics● Arises from glial cells● The most common site of gliomas is the brain● Make up ~30% of all brain and central nervous
system tumors and 80% of all malignant brain tumors
● Low-grade gliomas [WHO grade II] are well-differentiated (not anaplastic); these are benign and portend a better prognosis for the patient
● High-grade [WHO grade III–IV] gliomas are undifferentiated or anaplastic; these are malignant and carry a worse prognosis
Prognosis
● Prognosis largely determined by grade● For low grade gliomas, median survival is 12-17
years● Anaplastic astrocytoma (Grade III), median
survival 3 years● Glioblastoma Multiforme (Grade IV), median
survival 14 months (without treatment, 4 months)
Treatment
● Grade IV – debulking with concurrent irradiation and temozolomide, then 6 months of temozolomide
● Grade III – debulking with irradiation. Temozolomide if recurrence
● Low grade – controversial. Debulking. Irradiation if progression? Temozolomide?
● Despite treatment, high grade gliomas often recur
Recurrence or radionecrosis?
● Due to the high risk of recurrence, post-treatment imaging must be able to distinguish between recurrence, pseudo-progression, and radiation necrosis
● Imaging options include MR, PET, and SPECT
MRI
PET
Case Report: 17M with headache, blurred vision, left upper limb weakness
Dx: GBM, 5 months post chemo-rads
FDG-PET/CT
FCH-PET/CT
Sestamibi-SPECT/CT
Sestamibi
● Monovalent lipophilic cation● No tissue specificity● Doesn't cross the BBB● No contrast nephropathy, no NSF, no
significant anaphylaxis risk
Single Photon Emission Computed Tomography (SPECT)
● 3D imaging using a gamma camera● Many different possible radiotracers depending
on the application● For glioma imaging, perfusion agents are
generally used e.g. Sestamibi, Tetrofosmin, Thallium
SPECT
LeJeune et al
● Largest (N=201) MIBI study to date● For all grades, Sn 90%, Sp 91.5%, Accy 90.5%● Path/clinical follow-up as gold standard● False positives in 3 patients - 2 inflammation (?)
1 unknown● False negatives in 5 – intact BBB (?)● SPECT positive earlier than MR
Interpretation
Advantages
● Accuracy comparable to MR Spectroscopy● No risk to the patient (besides radiation)● High inter-observer agreement● Positive earlier than MR● No patient restrictions● Cost ($215.95)
Disadvantages
● Radiation exposure (~4.5 mSv < 2 yrs background radiation)
Fusion Imaging